Avivagen Signs New Distribution Partner in Vietnam to Support Southeast Asian Growth

Rhea-AI Summary

Avivagen Inc. (OTCQB: VIVXF) has signed a distribution agreement with Nong San Viet Co., Ltd to expand its market presence in Vietnam. This partnership will promote Avivagen's oxidized carotenoid-based feed additives, which enhance animal health and performance. Vietnam is highlighted as a major opportunity, being the largest feed market in Southeast Asia, with total feed consumption exceeding 32 million metric tons in 2020. The agreement follows regulatory approvals and aims to leverage growing interest from local producers.

Positive

• New distribution agreement with Nong San Viet Co., Ltd for market expansion in Vietnam.
• Vietnam represents the largest feed market in Southeast Asia, with significant growth potential.

Negative

• None.

OTTAWA, Ontario--(BUSINESS WIRE)-- Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, is pleased to announce that it has signed a new distribution agreement with Nong San Viet Co., Ltd (VIET ACC) to support the company’s continued market expansion for its oxidized carotenoid-based feed additive product in Vietnam.

Founded in 2005, VIET ACC has established itself as a premier distributor of major feed ingredients and feed additive brands to major producers throughout Vietnam. With a primary focus on poultry and swine, the company is a leader in the distribution of premix and feed additives, as well as in the trading of agricultural commodities for use in livestock and aquaculture.

“Vietnam represents significant market opportunity for Avivagen, and we’re excited to be working with Viet ACC to better access the largest feed market in Southeast Asia,” says Kym Anthony, Chief Executive Officer, Avivagen. “We’ve seen strong interest from producers across Vietnam since receiving regulatory approval earlier this year and hope to see equally strong results from this new relationship over the coming months and years.”

Vietnam represents the largest feed market in Southeast Asia according to a report by the US Grains Council, which indicates total annual feed consumption of over 32 MMT in 2020. Additionally, The Grains Council report states that Vietnam is a strong growth market which is expected to surpass 35 MMT of feed within the next few years.ⁱ Production within the country is dominated by swine, with feed for swine accounting for approximately 38% of total feed, followed by poultry accounting for 21.6% of total feed. (2020)ⁱⁱ.

About Avivagen
Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance. It is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada. For more information, visit www.avivagen.com. The contents of the website are expressly not incorporated by reference in this press release.

About OxC-beta™ Technology and OxC-beta™ Livestock
Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about β-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function, the technology provides a non-antibiotic means of promoting health and growth. OxC-beta™ Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. The product is currently available for sale in the United States, Philippines, Mexico, Taiwan, New Zealand, Thailand, Brazil, Australia, and Malaysia.

Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.

Forward Looking Statements
This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “aim”, “anticipate”, “appear”, “believe”, “consider”, “could”, “estimate”, “expect”, “if”, “intend”, “goal”, “hope”, “likely”, “may”, “plan”, “possibly”, “potentially”, “pursue”, “seem”, “should”, “whether”, “will”, “would” and similar expressions.

Statements set out in this news release relating to the future growth and prospects for Avivagen and the possibility for OxC-beta™ Livestock to replace antibiotics in livestock feeds as growth promoters are forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. For instance, Avivagen’s products may not gain market acceptance or regulatory approval in new jurisdictions or for new applications and may not be widely accepted as a replacement for antibiotics as growth promoters in livestock feeds due to many factors, many of which are outside of Avivagen’s control. Readers are referred to the risk factors associated with the business of Avivagen set out in Avivagen’s most recent management’s discussion and analysis of financial condition available at www.SEDAR.com. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Copyright © 2022 Avivagen Inc.

^{________________________________
i} https://grains.org/markets-tools-data/markets/market-profiles/vietnam/
ⁱⁱ https://public.tableau.com/app/profile/alltech.digital/viz/AlltechGlobalFeedSurvey2021/AlltechGlobalFeedSurvey2021

View source version on businesswire.com: https://www.businesswire.com/news/home/20220530005017/en/

Avivagen Inc.

Drew Basek

Director of Investor Relations

100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6 Phone: 416-540-0733

E-mail: d.basek@avivagen.com

Kym Anthony

Chief Executive Officer

100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6 Head Office Phone: 613-949-8164

Website: www.avivagen.com

Source: Avivagen Inc.

FAQ

What recent agreement has Avivagen Inc. entered into regarding its products?

Avivagen Inc. has signed a distribution agreement with Nong San Viet Co., Ltd to expand its market presence in Vietnam.

Why is the Vietnamese market significant for Avivagen Inc.?

Vietnam is the largest feed market in Southeast Asia, with total feed consumption exceeding 32 million metric tons, presenting significant growth opportunities.

What type of product is Avivagen promoting in Vietnam?

Avivagen is promoting its oxidized carotenoid-based feed additives designed to enhance animal health and performance.

What regulatory approvals has Avivagen received for its products?

Avivagen has received regulatory approval for its feed additives in Vietnam earlier this year, leading to strong interest from local producers.